NIH Advances Clinical Research on Kratom-Derived Compound for Opioid Use Disorder Treatment
The National Institutes of Health (NIH) has reached an important milestone in the search for new treatments for opioid use disorder (OUD). The agency announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for mitragynine, the primary naturally occurring active compound found in Mitragyna speciosa, commonly known as kratom.
The IND approval clears the way for an NIH-sponsored Phase I clinical trial, marking the first time a purified formulation of mitragynine will be evaluated in humans as a potential treatment for opioid use disorder. Researchers hope the study will provide valuable information about the compound's safety and determine whether it could eventually become another evidence-based option for people recovering from opioid addiction.
A Significant Step Toward New Treatment Options
Opioid use disorder continues to affect millions of Americans and remains a major contributor to overdose deaths nationwide. Although effective treatments such as methadone and buprenorphine are available, many patients still face barriers to care, underscoring the need for additional therapeutic options.
According to Dr. Nora Volkow, Director of the NIH's National Institute on Drug Abuse (NIDA), the FDA's acceptance of the IND represents a meaningful advancement in addiction research.
She noted that expanding the range of available treatments could improve recovery opportunities for individuals living with opioid use disorder while helping address the ongoing overdose crisis driven largely by highly potent synthetic opioids such as FYL.
What Is Mitragynine?
Mitragynine is the principal psychoactive alkaloid naturally found in kratom, a tropical tree native to Southeast Asia.
For centuries, kratom leaves have been used in some regions of Southeast Asia for traditional medicinal purposes. More recently, interest in the plant has grown internationally as some individuals report using kratom to help manage opioid withdrawal symptoms, chronic pain, fatigue, and other conditions.
Scientists believe many of kratom's effects stem from mitragynine, which interacts with opioid receptors in the body after it is slowly converted into other active metabolites.
Unlike crude kratom products sold commercially, however, the upcoming clinical trial will use a highly purified pharmaceutical-grade formulation of mitragynine developed specifically for scientific research.
Years of Research Led to This Point
The purified mitragynine formulation did not emerge overnight.
Researchers from the NIH and the University of Florida collaborated extensively to develop the compound and conduct the laboratory and preclinical studies required before submitting the IND application to the FDA.
Those studies evaluated the compound in animal models to better understand its pharmacology and safety profile.
According to investigators, mitragynine demonstrated encouraging results during preclinical testing. Across multiple dosing levels, researchers did not identify major safety concerns that would prevent moving forward into carefully monitored human studies.
These findings provided the scientific foundation necessary for the FDA to authorize the next phase of research.
Human Studies Begin for the First Time
Although mitragynine has attracted significant public interest over the past several years, the purified compound itself has never been formally studied in humans under the rigorous standards required for pharmaceutical development.
The newly approved Phase I trial will change that.
NIH researchers plan to conduct a randomized, double-blind, placebo-controlled clinical study, widely considered the gold standard for evaluating new medications.
The primary objective will be to determine whether the purified mitragynine formulation is safe and well tolerated in healthy human participants.
Investigators will closely monitor participants for side effects, measure how the body processes the compound, and collect data that may support future studies involving individuals with opioid use disorder.
Why Researchers Are Interested
Scientists emphasize that the goal of this research is not to evaluate commercially available kratom products.
Instead, they are studying a precisely manufactured pharmaceutical formulation containing a known amount of purified mitragynine under carefully controlled clinical conditions.
Commercial kratom products can vary significantly in purity, potency, and chemical composition. Some products may contain contaminants or additional alkaloids that complicate efforts to evaluate safety and effectiveness.
By isolating mitragynine and producing it according to pharmaceutical standards, researchers can investigate its therapeutic potential without the variability associated with unregulated botanical products.
A Potential Addition to Addiction Treatment
Current medications for opioid use disorder have helped countless individuals achieve recovery by reducing cravings, easing withdrawal symptoms, and lowering overdose risk.
Even so, experts acknowledge that no single treatment works for every patient.
If future clinical trials demonstrate that mitragynine is both safe and effective, it could eventually provide another option for clinicians treating opioid use disorder.
Researchers believe expanding the number of evidence-based therapies may improve access to care and allow treatment to be better tailored to individual patient needs.
Dr. Joni Rutter, Director of the NIH National Center for Advancing Translational Sciences (NCATS), said years of laboratory research have shown promising potential, and investigators are now eager to determine whether those findings translate into human studies.
She expressed hope that the research could ultimately contribute to new recovery options for people living with opioid use disorder.
Part of the NIH HEAL Initiative
The clinical trial is being conducted as part of the Helping to End Addiction Long-term® (HEAL) Initiative, a large-scale NIH research program focused on improving pain management, preventing addiction, and expanding treatments for substance use disorders.
The initiative supports hundreds of research projects across the United States aimed at developing safer pain therapies, improving overdose prevention strategies, and identifying innovative approaches for treating opioid addiction.
The mitragynine trial represents another component of that broader effort to address one of the nation's most pressing public health challenges.
Looking Ahead
While the FDA's acceptance of the IND application represents an important milestone, researchers caution that this is only the beginning of the clinical evaluation process.
Phase I trials are designed primarily to assess safety, not effectiveness. Additional studies involving larger groups of participants with opioid use disorder would be required before mitragynine could be considered for regulatory approval as a treatment.
Nevertheless, the launch of the first human trial marks a significant step forward in understanding whether this naturally derived compound may one day become part of the growing toolkit used to treat opioid addiction.
As the opioid epidemic continues to evolve, the development of new evidence-based therapies remains a critical priority. By exploring innovative compounds such as purified mitragynine through rigorous scientific research, investigators hope to expand treatment options and improve recovery outcomes for individuals affected by opioid use disorder.
Source: NIH